Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APGE NASDAQ:CGON NASDAQ:DNTH NASDAQ:OCS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPGEApogee Therapeutics$86.92-4.4%$83.96$34.34▼$95.32$5.38B0.62960,007 shs1.31 million shsCGONCG Oncology$53.72-4.2%$65.98$23.65▼$75.50$4.74B0.31958,797 shs967,310 shsDNTHDianthus Therapeutics$80.51-4.3%$87.31$16.64▼$96.50$4.40B1.18556,580 shs835,882 shsOCSOculis$11.21-5.2%$26.45$11.17▼$34.47$650M0.231.10 million shs869,797 shsThe Rise of the RobotsRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and industrial operations. This report explores the rise of “Physical AI,” highlights four key ways investors can gain exposure to the robotics revolution, and profiles seven leading companies positioned to benefit from the growing demand for intelligent automation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPGEApogee Therapeutics-3.83%+5.82%+2.82%+18.99%+138.14%CGONCG Oncology-4.23%-13.76%-21.01%-13.19%+102.11%DNTHDianthus Therapeutics-4.30%-13.44%-10.96%+23.48%+348.27%OCSOculis-5.24%-50.62%-62.10%-58.42%-41.46%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPGEApogee Therapeutics$86.92-4.4%$83.96$34.34▼$95.32$5.38B0.62960,007 shs1.31 million shsCGONCG Oncology$53.72-4.2%$65.98$23.65▼$75.50$4.74B0.31958,797 shs967,310 shsDNTHDianthus Therapeutics$80.51-4.3%$87.31$16.64▼$96.50$4.40B1.18556,580 shs835,882 shsOCSOculis$11.21-5.2%$26.45$11.17▼$34.47$650M0.231.10 million shs869,797 shsThe Rise of the RobotsRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and industrial operations. This report explores the rise of “Physical AI,” highlights four key ways investors can gain exposure to the robotics revolution, and profiles seven leading companies positioned to benefit from the growing demand for intelligent automation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPGEApogee Therapeutics-3.83%+5.82%+2.82%+18.99%+138.14%CGONCG Oncology-4.23%-13.76%-21.01%-13.19%+102.11%DNTHDianthus Therapeutics-4.30%-13.44%-10.96%+23.48%+348.27%OCSOculis-5.24%-50.62%-62.10%-58.42%-41.46%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPGEApogee Therapeutics 2.74Moderate Buy$113.6330.72% UpsideCGONCG Oncology 2.71Moderate Buy$81.7352.14% UpsideDNTHDianthus Therapeutics 3.00Buy$117.8246.34% UpsideOCSOculis 2.80Moderate Buy$38.33241.96% UpsideCurrent Analyst Ratings BreakdownLatest OCS, CGON, APGE, and DNTH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2026OCSOculis JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$42.00 ➝ $23.006/1/2026OCSOculis Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$49.00 ➝ $38.006/1/2026OCSOculis Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$50.00 ➝ $40.006/1/2026OCSOculis GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$75.00 ➝ $45.006/1/2026OCSOculis HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$47.00 ➝ $26.006/1/2026OCSOculis Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$46.00 ➝ $38.005/28/2026APGEApogee Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$89.005/28/2026APGEApogee Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold5/27/2026APGEApogee Therapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetHold$83.00 ➝ $81.005/27/2026APGEApogee Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$137.005/27/2026APGEApogee Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$120.00 ➝ $135.00(Data available from 6/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPGEApogee TherapeuticsN/AN/AN/AN/A$13.23 per shareN/ACGONCG Oncology$4.04M1,172.80N/AN/A$9.33 per share5.76DNTHDianthus Therapeutics$2.04M2,157.59N/AN/A$11.41 per share7.06OCSOculisN/AN/AN/AN/A$4.08 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPGEApogee Therapeutics-$255.84M-$4.33N/AN/AN/AN/A-32.64%-31.25%8/10/2026 (Estimated)CGONCG Oncology-$160.99M-$2.33N/AN/AN/AN/A-23.33%-22.24%8/7/2026 (Estimated)DNTHDianthus Therapeutics-$162.34M-$4.13N/AN/AN/A-12,998.50%-27.30%-25.91%8/6/2026 (Estimated)OCSOculis-$119.44M-$2.13N/AN/AN/A-8,460.67%-56.78%-45.62%8/6/2026 (Estimated)Latest OCS, CGON, APGE, and DNTH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026APGEApogee Therapeutics-$1.0658-$1.06+$0.0058-$1.06N/AN/A5/8/2026Q1 2026CGONCG Oncology-$0.58-$0.71-$0.13-$0.71$0.45 million$1.08 million5/8/2026Q1 2026OCSOculis-$0.49-$0.63-$0.14-$0.61$0.25 million$0.26 million5/5/2026Q1 2026DNTHDianthus Therapeutics-$1.0719-$0.85+$0.2219-$0.85$0.40 million$0.46 million3/9/2026Q4 2025DNTHDianthus Therapeutics-$0.97-$1.43-$0.46-$1.43$0.40 million$0.57 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAPGEApogee TherapeuticsN/AN/AN/AN/AN/ACGONCG OncologyN/AN/AN/AN/AN/ADNTHDianthus TherapeuticsN/AN/AN/AN/AN/AOCSOculisN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPGEApogee TherapeuticsN/A32.5932.59CGONCG OncologyN/A31.3031.25DNTHDianthus TherapeuticsN/A29.2529.25OCSOculis0.015.185.18Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPGEApogee Therapeutics79.04%CGONCG Oncology26.56%DNTHDianthus Therapeutics47.53%OCSOculis22.30%Insider OwnershipCompanyInsider OwnershipAPGEApogee Therapeutics24.30%CGONCG Oncology4.80%DNTHDianthus Therapeutics3.02%OCSOculisN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPGEApogee Therapeutics9161.90 million46.86 millionOptionableCGONCG Oncology6188.20 million83.97 millionOptionableDNTHDianthus Therapeutics8054.67 million53.02 millionOptionableOCSOculis257.98 millionN/ANot OptionableOCS, CGON, APGE, and DNTH HeadlinesRecent News About These CompaniesOCS Investors Have Opportunity to Join Oculis Holding AG Fraud Investigation with the Schall Law FirmJune 4 at 5:06 PM | businesswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCSJune 4 at 10:00 AM | prnewswire.comLevi & Korsinsky Announces Investigation of Securities Claims Against Oculis Holding AG (OCS)June 4 at 9:00 AM | globenewswire.comOculis (NASDAQ:OCS) Given New $23.00 Price Target at JPMorgan Chase & Co.June 4 at 3:39 AM | americanbankingnews.comDiabetic macular edema eye drop from Oculis fails to meet primary endpointJune 3 at 6:57 PM | healio.comHOCS Investor Alert: Levi & Korsinsky Investigates Oculis Holding AG (OCS) for Potential Securities FraudJune 3 at 9:00 AM | businesswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCSJune 2, 2026 | globenewswire.comOculis shifts focus after phase III DME disappointmentJune 2, 2026 | bioworld.comBOculis Holding: Study Setback For Eye Drop Therapy Suggests Hold RatingJune 2, 2026 | seekingalpha.comOculis Holding AG Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information about Potentially Recovering Their LossesJune 2, 2026 | globenewswire.comOCS SHAREHOLDER INVESTIGATION: SueWallSt Investigates Oculis Holding AG for Possible Securities Law ViolationsJune 2, 2026 | prnewswire.comOculis Holding AG Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Oculis Holding AG (OCS)June 1, 2026 | prnewswire.comOCS ALERT: Levi & Korsinsky Investigates Oculis Holding AG for Possible Securities Fraud ViolationsJune 1, 2026 | markets.businessinsider.comOCS ALERT: Levi & Korsinsky Investigates Oculis Holding AG for Possible Securities Fraud ViolationsJune 1, 2026 | newsfilecorp.comNOculis Shelves FDA Filing After Phase 3 DME Trials Miss Key Vision GoalsMay 31, 2026 | marketbeat.comOculis (NASDAQ:OCS) Sees Large Volume Increase - What's Next?May 31, 2026 | americanbankingnews.comOculis falls on late-stage trial setback for eye therapyMay 30, 2026 | msn.comOCS Stock Drops Over 23% — Eye Drop Trial For Diabetic Vision Loss Misses TargetMay 30, 2026 | finance.yahoo.comOculis Publishes Notifications of Transactions by Persons Discharging Managerial ResponsibilitiesMay 29, 2026 | globenewswire.comOculis Announces Phase 3 Trial Results for OCS-01 Eye Drops in Diabetic Macular Edema, Shifts Focus to Other Development ProgramsMay 29, 2026 | quiverquant.comQOculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular EdemaMay 29, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOCS, CGON, APGE, and DNTH Company DescriptionsApogee Therapeutics NASDAQ:APGE$86.92 -3.98 (-4.38%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$86.88 -0.03 (-0.04%) As of 06/5/2026 06:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.CG Oncology NASDAQ:CGON$53.72 -2.37 (-4.23%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$53.70 -0.02 (-0.04%) As of 06/5/2026 05:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.Dianthus Therapeutics NASDAQ:DNTH$80.51 -3.62 (-4.30%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$80.50 -0.01 (-0.01%) As of 06/5/2026 04:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.Oculis NASDAQ:OCS$11.21 -0.62 (-5.24%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$11.23 +0.02 (+0.15%) As of 06/5/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/01 - 06/05 Samsara Just Answered The AI Question—Is Wall Street Ready To Listen? A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? IREN's 800MW Bet Flips the AI Power Switch Buy the Dip? Broadcom's AI Moat Is Wider Than Ever CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip? The Market Has Ollie’s Bargain Outlet Completely Wrong Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
